CTOs on the Move

Queens-Long Island Medical Group, P.C.

www.qlimg.com

 
Queens-Long Island Medical Group, P.C. is a Garden City, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.qlimg.com
  • 1000 Zeckendorf Blvd
    Garden City, NY USA 11530
  • Phone: 516.542.5500

Executives

Name Title Contact Details

Similar Companies

Healthation

Healthation is a Lisle, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Future Health Concepts Inc

Future Health Concepts Inc is a Sanford, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zanthion

Zanthion protects the elderly from harm, automatically notifies near responders to avoid catastrophic damage, offers solace until help arrives, predicts future needs through artificial intelligence, and connects seniors to the world and their community. Zanthion is a pioneer in changing our social environment with future vision and use case (solution based) systems that improve the world based on open source, transparent, crowdsourced economic mechanisms that accurately assess what happened, inform the correct resources that the event has occurred, provide resources to the problem efficiently, and keep track of the efficiency of fixing the non-conformity. Our platform is generic and it is open. We embrace a responsible future.

Los Ninos Services

Los Ninos Services is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avaxia Biologics

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.